Lv2
200 积分 2024-10-16 加入
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
6小时前
待确认
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
7小时前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
7天前
已完结
Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates
7天前
已完结
Review of Dose Justifications for Antibody-Drug Conjugate Approvals from Clinical Pharmacology Perspective: a Focus on Exposure-Response Analyses
7天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
10天前
已完结
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
25天前
已完结
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach
25天前
已完结
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin
25天前
已关闭
Automated microscopic image analysis for leukocytes identification: A survey
1个月前
已关闭
皖公网安备34019202002308
